Urologia Internationalis
Original Paper
Prognostic Significance of p53 Protein Overexpression in Transitional Cell Carcinoma of the Renal Pelvis and UreterJinza S.a · Takano Y.b · Iki M.c · Noguchi S.a · Masuda M.aaDepartment of Urology, Yokohama City University School of Medicine, Yokohama-shi, Kanagawa-ken; b Department of Pathology, Kitasato University School of Medicine, Sagamihara-shi, Kanagawa-ken, and c Department of Environmental Health, Fukui Medical School, Yoshida-gun, Fukui-ken, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 05, 1998
Issue release date: June 1998
Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 4
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Fifty-three patients with invasive transitional cell carcinoma of the renal pelvis and ureter were studied for p53 protein overexpression by immunohistochemistry. Overexpression of p53 protein was observed in 19 patients (35.8%). There was a significant correlation between overexpression of p53 protein and histologic grade (p < 0.01). However, there was no correlation found between p53 immunoreactivity and pathologic stage. By univariate survival analysis, a significant difference in cumulative survival was observed between stage pT2 and stage pT3 or pT4 tumors (p < 0.05). The difference in survival between patients with p53-positive and negative tumors did not reach statistical significance (0.05 < p < 0.1). Multivariate analysis revealed that pathologic stage had an independent prognostic value (p < 0.05). The independent prognostic value of p53 protein overexpression did not quite reach statistical significance (p = 0.07). p53 protein nuclear overexpression appears to be a relatively weak prognostic indicator for patients with invasive transitional cell carcinoma of the renal pelvis and ureter.
Related Articles:
References
- Huben RP, Mounzer AM, Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988;62:2016–2020.
- Akaza H, Koiso K, Niijima T: Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer 1987;59:1369–1375.
- Charbit L, Gendreau MC, Mee S, Cukier J: Tumors of the upper urinary tract: 10 years of experience. J Urol 1991;146:1243–1246.
- Babaian RJ, Johnson DE: Primary carcinoma of the ureter. J Urol 1980;123:357–359.
- Das AK, Carson CC, Bolick D, Paulson DF: Primary carcinoma of the upper urinary tract. Cancer 1990;66:1919–1923.
- Jinza S, Iki M, Noguchi S, Shuin T, Kubota Y, Masuda M: Nucleolar organizer regions: A new prognostic factor for upper tract urothelial cancer. J Urol 1995;154:1688–1692.
- Masuda M, Iki M, Takano Y, Asakura T, Noguchi S, Ikeda I, Kubota Y, Hosaka M: Prognostic significance of Ki-67 labeling index in urothelial tumors of the renal pelvis and ureter. J Urol 1996;155:1877–1881.
- Blute ML, Tsushima K, Farrow GM, Therneau TM, Lieber MM: Transitional cell carcinoma of the renal pelvis: Nuclear deoxyribonucleic acid ploidy studied by flow cytometry. J Urol 1988;140:944–949.
- Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992;70:523–526.
- Finlay CA, Hinds PW, Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 1989;57:1083–1093.
- Fields S, Jang SK: Presence of a potent transcriptional activating sequence in the p53 protein. Science 1990;249:1046–1048.
- Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen S, Skinner DG, Jones PA, Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389–1397.
- Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR: Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622–1627.
- Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 1991;88:10657–10661.
- Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675–679.
- Vet JAM, Bringuier PP, Poddighe PJ, Karthaus HFM, Debruyne FMJ, Schalken JA: p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994;70:496–500.
- Underwood MA, Reeves J, Smith G, Gardiner DS, Scott R, Bartlett J, Cooke TG: Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996;77:659–666.
- Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393–1398.
- Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Association of p53 nuclear overexpression in carcinoma in situ of the bladder. J Urol 1994;152:388–392.
- Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365–370.
- Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–1264.
- Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993;85:53–59.
- Terrell RB, Cheville JC, See WA, Cohen MB: Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. J Urol 1995;154:1342–1347.
- Nakanishi K, Kawai T, Torikata C: Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 1996;27:1336–1340.
- Furihata M, Sonobe H, Ohtski Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N: Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol 1996;178:133–139.
-
Hermaneck P, Sobin L: TNM Classification of Malignant Tumors: Renal Pelvis and Ureter, ed 4. New York, Springer 1992, pp 151–153.
- Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Mamilton S, Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717–7722.
Article / Publication Details
Published online: June 05, 1998
Issue release date: June 1998
Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 4
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
